BioMarin Pharmaceutical (BMRN) Competitors $54.36 -0.78 (-1.41%) Closing price 04:00 PM EasternExtended Trading$54.86 +0.49 (+0.91%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BMRN vs. BIIB, UTHR, INCY, NBIX, EXAS, EXEL, MDGL, IONS, HALO, and RGENShould you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Halozyme Therapeutics (HALO), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. BioMarin Pharmaceutical vs. Its Competitors Biogen United Therapeutics Incyte Neurocrine Biosciences Exact Sciences Exelixis Madrigal Pharmaceuticals Ionis Pharmaceuticals Halozyme Therapeutics Repligen BioMarin Pharmaceutical (NASDAQ:BMRN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership. Do analysts prefer BMRN or BIIB? BioMarin Pharmaceutical presently has a consensus target price of $92.60, suggesting a potential upside of 70.35%. Biogen has a consensus target price of $181.65, suggesting a potential upside of 27.48%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, equities analysts plainly believe BioMarin Pharmaceutical is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioMarin Pharmaceutical 0 Sell rating(s) 8 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.64Biogen 0 Sell rating(s) 21 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.32 Which has higher earnings & valuation, BMRN or BIIB? Biogen has higher revenue and earnings than BioMarin Pharmaceutical. Biogen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioMarin Pharmaceutical$3.06B3.41$426.86M$3.3716.13Biogen$9.68B2.16$1.63B$10.4613.62 Is BMRN or BIIB more profitable? BioMarin Pharmaceutical has a net margin of 21.45% compared to Biogen's net margin of 15.31%. Biogen's return on equity of 13.85% beat BioMarin Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets BioMarin Pharmaceutical21.45% 12.59% 10.13% Biogen 15.31%13.85%8.32% Which has more volatility and risk, BMRN or BIIB? BioMarin Pharmaceutical has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Do insiders and institutionals have more ownership in BMRN or BIIB? 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.9% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor BMRN or BIIB? In the previous week, Biogen had 6 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 24 mentions for Biogen and 18 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.16 beat Biogen's score of 1.04 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 10 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 15 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBioMarin Pharmaceutical beats Biogen on 11 of the 16 factors compared between the two stocks. Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRN vs. The Competition Export to ExcelMetricBioMarin PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.44B$3.13B$5.76B$10.42BDividend YieldN/A2.37%5.74%4.63%P/E Ratio16.1320.6576.5526.73Price / Sales3.41386.12496.21162.19Price / Cash16.7545.3237.1760.63Price / Book1.839.6613.726.40Net Income$426.86M-$53.02M$3.29B$271.62M7 Day Performance0.50%1.09%1.03%2.85%1 Month Performance-5.15%7.93%6.32%9.64%1 Year Performance-23.88%10.48%81.16%31.62% BioMarin Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRNBioMarin Pharmaceutical4.9607 of 5 stars$54.36-1.4%$92.60+70.3%-22.5%$10.44B$3.06B16.133,040Positive NewsShort Interest ↑High Trading VolumeBIIBBiogen4.6897 of 5 stars$141.35+0.5%$185.74+31.4%-27.2%$20.72B$9.68B13.517,605Positive NewsUTHRUnited Therapeutics4.7371 of 5 stars$394.62-1.5%$429.62+8.9%+19.6%$17.80B$2.88B15.401,305Positive NewsInsider TradeINCYIncyte4.7761 of 5 stars$86.56-0.1%$82.53-4.7%+32.0%$16.90B$4.24B19.672,617Trending NewsAnalyst ForecastShort Interest ↓NBIXNeurocrine Biosciences4.6303 of 5 stars$143.80-0.2%$160.00+11.3%+21.5%$14.26B$2.36B42.541,800Positive NewsEXASExact Sciences4.8249 of 5 stars$53.89+0.1%$67.05+24.4%-22.6%$10.20B$2.76B-9.927,000Short Interest ↓EXELExelixis4.6696 of 5 stars$37.69-0.5%$44.06+16.9%+50.8%$10.15B$2.17B18.121,147Positive NewsAnalyst UpgradeMDGLMadrigal Pharmaceuticals3.9931 of 5 stars$453.80+4.8%$471.13+3.8%+89.0%$10.07B$180.13M-35.3290IONSIonis Pharmaceuticals3.9407 of 5 stars$61.00-0.4%$67.88+11.3%+45.8%$9.72B$705M-33.151,069Insider TradeAnalyst RevisionHALOHalozyme Therapeutics4.5873 of 5 stars$75.85+1.2%$67.11-11.5%+23.1%$8.87B$1.02B17.36390Positive NewsRGENRepligen4.8369 of 5 stars$120.70-3.1%$169.55+40.5%-12.4%$6.79B$634.44M-482.781,778 Related Companies and Tools Related Companies BIIB Competitors UTHR Competitors INCY Competitors NBIX Competitors EXAS Competitors EXEL Competitors MDGL Competitors IONS Competitors HALO Competitors RGEN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRN) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BMRN Stock Alerts